-
CUCrowdhelix User
Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: HORIZON-HLTH-2026-01-DISEASE-11
Project Proposal
-
-
CUCrowdhelix User
Join the Open Session of the EIC Cell & Gene Therapy Annual Portfolio Meeting
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the granting authority. Neither the European Union nor the granting authority can be held responsible for them. This project has received funding from the European Union’s Horizon 2020 or Horizon Europe research and innovation programme under grant agreement No 101070922.
Funded by
the European Union -
-
CUCrowdhelix User
Seeking international collaborators for "Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders"
Project Proposal
-
-
Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF
Acute-on-chronic liver failure is associated with severe liver inflammation and poor short-term survival. Therefore, effective treatments are urgen...
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 945096.
Funded by
the European Union -
CGT 4.0: a distant dream or inevitable future? Smart process automation is critical to make efficient scalability of CGT manufacturing a reality
Collaboratively developed by the PAT4CGT consortium, the article describes what we believe are the three layers needed to bring Industry 4.0 to Cel...
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the granting authority. Neither the European Union nor the granting authority can be held responsible for them. This project has received funding from the European Union’s Horizon 2020 or Horizon Europe research and innovation programme under grant agreement No 101070922.
Funded by
the European Union -
Watch the First CGT Helix Event
On 18 June 2024, project PAT4CGT delivered its first online CGT Helix event "Collaborative Frontiers: Advancing CGT Manufacturing Technologies". W...
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the granting authority. Neither the European Union nor the granting authority can be held responsible for them. This project has received funding from the European Union’s Horizon 2020 or Horizon Europe research and innovation programme under grant agreement No 101070922.
Funded by
the European Union -
-
Chemotherapy Device for Imatinib Drug Monitoring
Background - The effectiveness of many anticancer drugs varies greatly from patient to patient, with risks of incorrect dosages and adverse side ef...
-
Anti-Cancer Efficient and Non-Toxic Palladium Compounds
Background - Platinum-based antineoplastic drugs have been used since the late 1970s, although they sometimes show significant nephro- and neurotox...
-
Bicyclic Peptide Inhibitors of the Human Urokinase-Type Plasminogen Activator (HUPA)
Background - Bicyclic peptides are small polypeptides that exhibit properties typical of both monoclonal antibodies (high target specificity and af...
-
Dynamics of a "Healthy" Viable Microbiome to Prevent Diseases
Background - Research at Ca Foscari Venice University is focused on understanding what constitutes a “healthy” microbiome in terms of composition,...
-
Reversible Monoacylglycerol Lipase (MAGL) Inhibitors for Neurodegenerative Pathologies and Tumour Treatment
Background - The enzyme monoacylglycerol lipase (MAGL), which is part of the endocannabinoid system (ECS), has therapeutic potential for the treatm...
-
Less Toxic Chemotherapy with Palladium
Background - Targeted, efficient and non-toxic anti-cancer drugs: a new class of palladium compounds could be used as innovative chemotherapeutic m...
-
Copper Compounds for the Treatment of Ovarian Cancer
Background - The present invention is a nanomaterial containing a pharmaceutical composition based on copper (II) nitroprusside (CuNP) for use in...
